Bristol Myers: marketing authorization application validated by the EMA
If approved, repotrectinib will offer a potentially first-in-class treatment for patients with these diseases in the European Union", emphasizes the US pharmaceutical company.
This application was based on data from the TRIDENT-1 and CARE registration trials showing robust responses and durable activity. Its validation launches the centralized review procedure of the EMA (European Medicines Agency).
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction